All News

Your daily dose of the clinical news you may have missed.

Data on use of lecanemab in real world clinical settings will come from a neurologic case series review and a retrospective chart review of long-term use, both in early AD.

Gepotidacin is the first new oral antibiotic for uncomplicated urinary tract infections in 30 years, offering an alternative amid rising antibiotic resistance.

More than one-third of study participants with TRD had failed to get relief from 4 or more antidepressants, calling treatment experiences a "trial and error" process.

ACC 2025: Black women and women in Southern states faced significantly higher rates of maternal mortality, according to a new study.

Rates of preventable deaths are rising in every US state, according to a new study, defying the country's top-ranking spending on health care.

Your daily dose of the clinical news you may have missed.

Adding a deadline to a mailed invitation for FIT colorectal cancer screening resulted in improved return rates, according to new research.

For the same level of baseline health, the increase in risk related to each of 8 key CV risk factors appears significantly higher in women than in men.

The reductions observed in all-cause mortality (49%) and MACE (39%) in high-risk patients compared with statin monotherapy could be practice changing, researchers said.

Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.

AAD 2025: Raj Chovatiya, MD, PhD, MSCI, well-known physician scientist, says underrepresentation in clinical trials of those with skin of color precludes an evidence-based answer.

In a small study of adults genetically predisposed to early-onset dementia, anti-amyloid treatment to remove plaque reduced risk of developing symptoms by 50%.

Researchers recommend expanding antimicrobial stewardship efforts to better track and reduce unnecessary antibiotic use.

The greatest risk for developing cancer faces residents of South Dakota, where radon levels are the nation's highest, and ranks for alcohol consumption and obesity are poor.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

Your daily dose of the clinical news you may have missed.

Raj Chovatiya, MD, PhD, MSCI, discusses the complex and widely variable influences that affect the manifestations and burden of atopic dermatitis across populations.